Bulletin of Pharmaceutical Research 2026;16(2):208
An Official Publication of Association of Pharmacy Professionals
ISSN: 2249-6041 (Print); ISSN: 2249-9245 (Online)
DOI: 10.21276/bpr.2026.16.2.2

REVIEW ARTICLE

ADJUNCT NEUROPROTECTIVE THERAPIES IN NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY: A PRECLINICAL REVIEW OF VITAMIN E AND COENZYME Q10

Rajat Singh Rathore[1], Naveen Gupta[1], Rita Mourya[2], Deepa Iyer[3]* and Suprati Singh[4]

[1]Patel College of Pharmacy, Madhyanchal Professional University, Bhopal-462044, Madhya Pradesh, India. [2]School of Pharmacy, SAM Global University, Bhopal-462021, Madhya Pradesh, India. [3]School of Pharmacy, SAGE University, Bhopal-462022, Madhya Pradesh, India. [4]Department of Biotechnology, Delhi Technological University, New Delhi-110042, India.

**E-mail*: deepaiyer2183@gmail.com
Tel.: +91 6261831656.

Received: Dec 15, 2025 / Revised: Jun 01, 2026 / Accepted: Jun 01, 2026

Neonatal hypoxic-ischemic encephalopathy (HIE) remains a leading cause of perinatal mortality and long-term neurological disability, affecting 1-3 per 1000 term births globally. Current therapeutic hypothermia provides only modest neuroprotection, with 45-50% of treated infants still experiencing death or major disability. Oxidative stress plays a central role in HIE pathophysiology, creating a compelling rationale for antioxidant-based neuroprotective strategies. This comprehensive review examines the neuroprotective potential of vitamin E and coenzyme Q10 (CoQ10) as targeted antioxidant interventions for combating oxidative stress in neonatal HIE. Preclinical evidence was analyzed from multiple animal models, examining mechanisms of neuroprotection, pharmacokinetic profiles, safety data, and therapeutic window analyses for both individual and combination therapy approaches.

Key words: HIE, Oxidative stress, Vitamin E, Coenzyme Q10, Neuroprotection, Antioxidants.

INTRODUCTION

Neonatal hypoxic-ischemic encephalopathy (HIE) (**Figure 1**) one of the most devastating perinatal complications, affecting approximately 1-3 per 1000 term births worldwide and serving as a leading cause of neonatal mortality and long-term neurological disability [1,2]. This condition arises from inadequate cerebral blood flow and oxygen delivery to the developing brain during the perinatal period, typically occurring during labor, delivery, or the immediate postnatal period. The clinical presentation of HIE varies considerably, ranging from mild neurological symptoms that may resolve spontaneously to severe encephalopathy characterized by seizures, altered consciousness, and profound motor dysfunction [3].

The basic hypoxic-ischemic insult sets off an intricate chain of molecular and cellular occurrences that make up the pathophysiology of HIE. A secondary phase of injury marked by dysfunction of mitochondria, oxidative stress, and inflammatory responses can continue for hours to days following the initial insult due to the initial energy failure, which causes membrane depolarization, elevated glutamate release, and calcium influx [4]. A crucial therapeutic window for neuroprotective therapies is provided by the biphasic nature of damage. The long-term effects of HIE are severe; survivors often suffer from cerebral palsy, intellectual incapacity, epilepsy, and sensory impairments that have a major negative influence on quality of life and place a significant

© APP




Fig. 1. Hypoxic-Ischemic Encephalopathy (Biphasic Injury Model)

financial strain on families and healthcare systems [5]. In order to reduce brain damage and enhance neurodevelopmental results, there is an urgent need for efficient neuroprotective treatments that may be used throughout the therapeutic window, given the diverse nature of HIE presentation and outcomes.

Current therapeutic approaches and limitations

The only proven neuroprotective therapy for moderate to severe HIE in term and late premature neonates is therapeutic hypothermia. It has been demonstrated that this intervention can lower mortality and significant neurodevelopmental disability at 18-24 months of age when it is started within six hours of birth and continued for 72 hrs [6]. However, therapeutic hypothermia only offers minimal neuroprotection despite its demonstrated effectiveness; 45-50% of treated infants still die or have significant disabilities, underscoring the urgent need for supplemental or alternative therapeutic approaches [7].

The limited effectiveness of hypothermia alone is not the only drawback of current treatment approaches. Cooling therapy is not commonly employed due to its limited therapeutic window, complicated regulations for implementation, and contraindications in patient populations.

Additionally, hypothermia does not directly address the underlying molecular causes of neuronal death, such as oxidative stress, inflammation, and excitotoxicity, which contribute to continuous brain damage. Instead, it mainly targets the secondary phase of injury through metabolic suppression. The outcomes of recent clinical trials exploring supplementary therapies including xenon, melatonin, and erythropoietin have been unreliable, with some promising preclinical findings failing to be translated into substantial clinical benefits [8]. The intricacy of HIE pathophysiology and the requirement for focused therapies that target certain molecular pathways implicated in hypoxic-ischemic brain injury are highlighted by this translational gap.

Rationale for antioxidant interventions

Due to a number of intrinsic factors, such as high oxygen consumption, a substantial amount of peroxidation-prone lipids, immature antioxidant defense systems, and an elevated iron content that catalyzes the formation of free radicals, the developing neonatal brain is particularly vulnerable to oxidative stress [9]. The production of reactive oxygen species (ROS) and reactive nitrogen species during hypoxic-ischemic injury greatly surpasses the brain's antioxidant capacity, resulting in DNA damage,

lipid peroxidation, protein oxidation, and eventually neuronal death.

Antioxidant-based neuroprotective strategies have excellent justification since oxidative stress plays a crucial part in the pathogenesis of HIE. By intercepting free radicals, chelating metal ions, and strengthening endogenous antioxidant defense systems, antioxidants could potentially be able to prevent the chain reaction of oxidative damage.

In addition to their superior safety profiles, excellent pharmacokinetic properties, and demonstrated neuroprotective effects in animal models of HIE, vitamin E and coenzyme Q10 have emerged as particularly attractive candidates among the numerous antioxidant chemicals investigated.

Coenzyme Q10, which functions as both a powerful antioxidant and a component of the mitochondrial electron transport chain, and vitamin E, a lipophilic antioxidant that shields cellular membranes from lipid peroxidation, represent mechanistically different but complementary strategies for reducing oxidative stress in neonatal HIE [10]. These antioxidants are promising candidates for clinical translation in the treatment of HIE due to the abundance of preclinical data indicating their neuroprotective effect and their proven safety in newborn populations.

Pathophysiology of oxidative stress in neonatal HIE

Mechanisms of Hypoxic-Ischemic Brain Injury

The pathophysiology of hypoxic-ischemic encephalopathy can be described by a biphasic pattern of brain damage, with a delayed secondary phase of neuronal death occurring after the initial shock. Inadequate oxygen delivery during the first hypoxic-ischemic event causes oxidative phosphorylation to fail and cellular ATP stores to be depleted. ATP-dependent ion pumps fail as a result of this energy crisis, which causes membrane depolarization, ionic homeostasis loss, and a significant calcium influx via voltage-gated calcium channels and NMDA receptors [11].

Instantaneously cell death through necrosis is a characteristic of the initial phase, especially in areas with high consumption of metabolites which include the thalamus, peri rolandic cortex, and basal ganglia.

Excitotoxicity, oxidative stress, inflammation, and programmed cell death are some of the interrelated phenomena that drive the subsequent phase of injury, which is a crucial therapeutic window. This delayed neuronal death is a desirable target for neuroprotective therapies since it can persist for hours or days following the initial trauma. Since reperfusion paradoxically enhances the production of reactive oxygen species while cellular antioxidant defenses remain weakened, the secondary injury phase is especially pertinent to oxidative stress mechanisms [12,13].

Role of reactive oxygen species in neuronal damage

The pathophysiology of hypoxic-ischemic brain injury depends heavily on reactive oxygen species, which are produced via a variety of mechanisms during the main and subsequent stages of the injury. Electron leakage and the production of superoxide anions result from the first hypoxic-ischemic insult's disruption of mitochondrial electron transport. Furthermore, during the reperfusion phase, the stimulation of enzymes such cyclooxygenase, NADPH oxidase, and xanthine oxidase leads to the generation of ROS [14]. Superoxide anions, hydrogen peroxide, hydroxyl radicals, and peroxynitrite, which is created when superoxide and nitric oxide interact, are the most harmful ROS. Because of their high reactivity and capacity to start lipid peroxidation chain reactions in cell membranes, hydroxyl radicals are particularly destructive [15].

Beyond lipid peroxidation, ROS-mediated damage encompasses DNA damage and protein oxidation. Cellular transport processes, cytoskeletal integrity, and enzymatic activities can all be impaired by the oxidative degradation of crucial cellular proteins. DNA oxidation exacerbates mitochondrial dysfunction and sustains oxidative stress in a self-reinforcing cycle, especially of mitochondrial DNA considering its close proximity to ROS production sites and limited repair pathways [16].

Oxidative stress cascade and secondary injury

The complex interaction of molecular processes in the oxidative stress cascade in neonatal HIE amplifies initial damage and spreads it to neighboring brain areas. An imbalance that promotes oxidative damage is caused by reduced antioxidant defense systems' inability to sufficiently counteract the elevated ROS generation after the initial shock. Due to

underdeveloped antioxidant systems of enzymes and low glutathione levels, this imbalance is especially noticeable in the newborn brain [17].

Oxidative damage spreads *via* a number of interrelated processes. As secondary messengers, lipid peroxidation products like malondialdehyde and 4-hydroxynonenal spread from their sites of origin to inflict distant cellular harm. These aldehydic compounds have a capacity to cross-link with DNA and proteins, which exacerbates cellular failure. Furthermore, redox-sensitive transcription factors such nuclear factor-κB are activated by oxidative stress, which results in the overexpression of inflammatory mediators that attract immune cells and intensify tissue damage [18].

Multiple phases of the generation of ROS describe the temporal advancement of oxidative stress in HIE. A subsequent peak after reperfusion follows the initial burst that occurs during the acute injury resulting in mitochondrial failure. Days later, when inflammatory cells penetrate injured brain areas and activated microglia produce more ROS by activating NADPH oxidase, a third phase may take place. This persistent oxidative stress offers numerous options for therapeutic intervention and leads to the spread of brain injury beyond the original sites of damage [11,19].

Developmental vulnerability of the neonatal brain

Since there are a number of distinct developmental traits that set the growing newborn brain apart from the mature brain, it is more susceptible to oxidative stress. When the transport of oxygen decreases, the fast rate of development of the brain during the perinatal period is linked to increased oxygen consumption and metabolic processes, which can lead to oxidative stress. Furthermore, the production of lipid-rich myelin sheaths that are especially susceptible to lipid peroxidation is a part of the myelination process, which is actively taking place in the neonatal brain [20].

Key antioxidant enzymes like catalase, glutathione peroxidase, and superoxide dismutase have a reduced activity in the newborn brain than in the adult brain due to developmentally immature antioxidant defense systems. Neonatal brain tissue also has a much lower content of glutathione, an essential intracellular antioxidant. The brain's ability to manage oxidative stress is restricted during this sensitive window caused by the developmental immaturity of antioxidant defenses [21].

Additionally, the neonatal brain has high concentrations of free iron, which triggers the Fenton reaction, which generates extremely reactive hydroxyl radicals. The risk of iron-catalyzed oxidative damage is elevated by iron accumulate in particular brain areas and immature iron-binding protein systems [22].

The vulnerability of the developing brain is also affected by its unique cellular makeup. Because of their high iron concentration and low antioxidant capacity, oligodendrocyte progenitor cells, which occur frequently throughout the perinatal period, are particularly prone to oxidative damage. The distinctive pattern of white matter damage seen in neonatal HIE, including periventricular leukomalacia and diffuse white matter destruction that can have a major impact on neurodevelopmental outcomes, can be addressed by the selective susceptible nature of these cells [23].

Vitamin E as a neuroprotective agent

Structure, types, and biological properties

The eight naturally occurring lipophilic substances that comprise up vitamin E include four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ) (**Figure 2**). All of these compounds have a chromanol ring structure with different side chain configurations and methylation patterns. Because of the liver's selective binding affinity for α-tocopherol transfer protein (α-TTP), α-tocopherol, the most physiologically active form, is more effectively maintained in human tissues [24]. The chemical structure of α-tocopherol includes a 16-carbon phytyl tail that fixes the molecule within cellular membranes and a chromanol head group that is responsible for antioxidant action.

Lipid peroxyl radicals can get phenolic hydrogen from the chromanol ring, creating a rather stable tocopheroxyl radical that stops lipid peroxidation chain processes. Furthermore, vitamin E has non-antioxidant properties that support its neuroprotective actions, such as controlling gene expression, enzyme activity, and cell signaling pathways [25].

Vitamin E is distributed in neural tissues in a specific manner, with synaptic membranes and myelin-rich white matter areas having the highest quantities. Vitamin E is transported across the blood-brain barrier by a facilitated diffusion procedure, with α-tocopherol exhibiting preferential uptake over other forms. during normal circumstances, brain vitamin E




Fig. 2. 2-D Structure of Four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ)
(a) α-tocopherol, (b) β-tocopherol, (c) γ-tocopherol, (d) δ-tocopherol, (e) α-tocotrienol
(f) β-tocotrienol, (g) γ-tocotrienol, (h) δ -tocotrienol

concentrations are between 10% and 20% of plasma levels; however, during oxidative stress, they can be considerably reduced [26].

Mechanisms of neuroprotection

Lipid peroxidation inhibition

Vitamin E's primary neuroprotective mechanism involves the inhibition of lipid peroxidation through its role as a chain-breaking antioxidant. During hypoxic-ischemic conditions, poly-unsaturated fatty acids in neuronal membranes become highly susceptible to oxidative attack by hydroxyl radicals and other ROS. The initiation of lipid peroxidation creates lipid radicals that propagate damage through chain reactions, ultimately leading to membrane dysfunction and cell death [27].

α-Tocopherol intercepts lipid peroxyl radicals with a rate constant of approximately 10^8 $M^{-1}s^{-1}$, effectively terminating the propagation phase of lipid peroxidation. The resulting tocopheroxyl radical is relatively unreactive and can be regenerated to active vitamin E through reduction by ascorbic acid or glutathione,

maintaining the antioxidant capacity of the system. Studies in neonatal HIE models demonstrate that vitamin E supplementation significantly reduces markers of lipid peroxidation including malondialdehyde and 4-hydroxynonenal in brain tissue [28].

The ability to safeguard opposed to lipid peroxidation is particularly significant in the developing brain since neuronal membranes carry large levels of arachidonic acid and docosahexaenoic acid (DHA). Nevertheless, being exceptionally prone to oxidative damage, these highly unsaturated fatty acids are crucial for healthy brain development. The exact positioning of vitamin E within membrane bilayers shields these fragile lipids from oxidative harm.

Membrane stabilization

In addition to its antioxidant qualities, vitamin E actively stabilizes membranes, which promotes neuroprotection. Membrane fluidity, permeability, and stability are affected by the integration of α-tocopherol's hydrophobic phytyl tail into the lipid bilayer. Ion channel activity, neurotransmitter release, and cellular communication constitute the ideal membrane characteristics required for healthy neuronal function that are maintained by this physical interaction [29].

Studies on vitamin E insufficiency have shown that low tocopherol levels cause altered phospholipid composition, increased membrane fragility, and reduced membrane integrity. Vitamin E administration may help maintain membrane integrity and stop secondary membrane-mediated damage in the context of HIE, when energy depletion and ionic imbalances impair normal membrane function.

Anti-inflammatory effects

By regulating the synthesis of inflammatory mediators and immune cell activation, vitamin E's strong anti-inflammatory qualities support neuroprotection in HIE. Tumor necrosis factor-α, interleukin-1β, and interleukin-6 are among the pro-inflammatory cytokines that are produced less frequently when α-tocopherol reduces activity of protein kinase C, important enzyme in inflammatory signaling pathways [30].

Suppression of nuclear factor-κB activation, a master regulator of inflammatory gene expression, is another aspect of vitamin E's anti-inflammatory properties. Vitamin E decreases the transcription of inflammatory genes and restricts the recruiting and activation of microglia and astrocytes in damaged brain areas by blocking the translocation of NF-κB to the nucleus. Furthermore, vitamin E increases the synthesis of anti-inflammatory mediators like interleukin-10, which aid in tissue regeneration and inflammation clearance.

Preclinical studies in HIE models

Numerous animal models of neonatal HIE have shown the neuroprotective effectiveness of vitamin E, according to extensive preclinical studies. The most popular model, which closely resembles the pathophysiology of human neonatal HIE, comprises unilateral carotid artery ligation followed by hypoxia exposure in postnatal day 7 rats. Research employing this paradigm has repeatedly demonstrated that vitamin E treatment improves neurological outcomes, preserves brain tissue architecture, and decreases infarct volume [31].

Vitamin E has been shown to have neuroprotective benefits in a variety of species, dosage methods, and timing regimens, indicating strong efficacy. According to dose-response studies, neuroprotection is best achieved at doses between 50 and 200 mg/kg; larger doses may have negative effects and offer no further benefit. According to most research, the therapeutic window for vitamin E administration lasts up to six hours after damage, which corresponds with the secondary injury phase of HIE pathogenesis [32].

Early vitamin E administration enhances long-term behavioral outcomes, such as learning, memory, and motor function, in addition to providing acute neuroprotection, according to long-term follow-up studies in animal models. When comparing vitamin E-treated rats to controls, histopathological investigation shows that hippocampal neurons are preserved, gliosis is decreased, and white matter integrity is preserved [33].

Dosage, administration, and bioavailability

Clinical recommendations are determined by safety profiles, tissue distribution, and bioavailability; the best vitamin E dosage strategy for neonatal HIE is still being researched. Effective dosages between 50 and 200 mg/kg body weight are suggested by preclinical research; they are usually given intraperitoneally or intravenously to guarantee quick systemic availability throughout the crucial treatment window [34].

Depending on the formulation and mode of administration, vitamin E's bioavailability varies greatly. When compared to oil-based formulations, water-soluble preparations like α-tocopheryl polyethylene glycol succinate (TPGS) show higher bioavailability. This is especially crucial for critically unwell neonates who may have reduced gastrointestinal absorption. Brain tissue levels approach therapeutic values 4-6 hrs after intravenous injection, while peak plasma concentrations are reached within 1-2 hrs.

With preferential formation in membrane-rich areas, vitamin E is distributed to brain tissue by enhanced transport across the blood-brain barrier. The degree of blood-brain barrier integrity (which is frequently disrupted in HIE), competition with endogenous tocopherols, and plasma protein binding are factors that influence brain penetration. Because of their immature pathways of metabolism and separate body composition from adults, neonatal individuals may have variable pharmacokinetics.

Safety profile and adverse effects

Even at high therapeutic dosages, vitamin E has been shown to have a very good safety profile in neonatal populations. Because of effective regulatory systems that prevent excessive accumulation, vitamin E's fat-soluble nature permits tissue buildup, but toxicity is uncommon. Studies on premature infants taking vitamin E supplements to prevent bronchopulmonary dysplasia and retinopathy of prematurity provide the majority of the safety information [35].

Prolongation of coagulation parameters as a result of interference with vitamin K-dependent clotting factors is the most often documented side effect of high-dose vitamin E. Usually, this impact is minor and reversible when stopped. High-dose vitamin E has been linked in rare cases to a higher risk of infection and necrotizing enterocolitis in premature newborns; however, the direct relationship is still debatable and may have more to do with particular formulations than vitamin E itself [36].

There are few restrictions on the use of vitamin E, and the main ones are recognized hypersensitivity to tocopherols or formulation ingredients. Neonates undergoing anticoagulant medication or those with significant coagulopathy should be treated with caution. While acute treatment for HIE usually entails short-term dosing that minimizes safety concerns, regular monitoring of coagulation parameters and vitamin E levels may be necessary throughout extended treatment cycles. With beneficial levels well below those linked to notable side effects, the therapeutic index for vitamin E in neonatal HIE seems promising. Vitamin E's potential clinical use in the management of HIE as either monotherapy or an adjuvant treatment with therapeutic hypothermia is supported by this safety margin and its proven use in newborn critical care units [37].

Coenzyme Q10 in neonatal neuroprotection

Structure and cellular functions

A crucial part of the mitochondrial electron transport chain, Coenzyme Q10 (CoQ10), sometimes referred to as ubiquinone, is a lipophilic benzoquinone derivative with a 10-unit isoprenoid side chain. The molecule can be found in three different redox states: totally reduced ubiquinol, partially reduced semiquinone radical, and fully oxidized ubiquinone. Its bioenergetic and antioxidant roles in cellular systems are based on this redox cycling capacity [38].

CoQ10's twin functions in energy production and antioxidant defense are reflected in its cellular distribution, with the brain, heart, and liver tissues rich in mitochondria, having the highest quantities. CoQ10 is mostly found in the inner mitochondrial membrane of cells, where it helps Complexes I/II and Complex III of the respiratory chain transfer electrons. CoQ10 is also found in other cellular membranes, such as the Golgi apparatus, endoplasmic reticulum, and plasma membrane, where it supports antioxidant defense and membrane stability [39]. Tyrosine, mevalonic acid, and many vitamins are among the many enzymes and cofactors needed in the intricate process of endogenous CoQ10 production. Most tissues have this biosynthetic potential, but during times of high metabolic demand or oxidative stress, synthesis may be inadequate. Lower CoQ10 concentrations in the developing newborn brain than in the adult brain may enhance susceptibility to oxidative damage and mitochondrial dysfunction during hypoxic-ischemic episodes [40].

Human tissues' levels of CoQ10 decrease with age and can be further reduced by a number of diseases, drugs, and dietary deficiencies. Exogenous supplementation is a logical therapeutic strategy in the context of neonatal HIE since oxidative stress, high metabolic

demands, and immature antioxidant systems may quickly deplete endogenous CoQ10 reserves.

Neuroprotective mechanisms

Mitochondrial electron transport enhancement

CoQ10 is necessary for effective ATP synthesis since its main biological role is to facilitate electron transport within the mitochondrial respiratory chain. Oxygen shortage, interruption of the electron transport chain, and resultant energy failure cause mitochondrial malfunction under hypoxic-ischemic circumstances. By promoting electron transport between respiratory complexes, CoQ10 supplementation can promote residual mitochondrial function even in low oxygen environments [41].

Beyond just producing ATP, improved mitochondrial function has a neuroprotective effect. Increased electron transport efficiency breaks the loop of oxidative damage that defines the secondary injury phase of HIE by reducing electron leakage and the ensuing production of superoxide. CoQ10 therapy maintains membrane potential and respiratory chain performance under simulated ischemia circumstances, according to studies employing isolated brain mitochondria from newborn mice [42].

When individual complexes are destroyed, CoQ10's capacity to transfer electrons between membrane-bound and mobile respiratory chain components offers flexibility in sustaining energy production. Because different parts of the brain may suffer from varying degrees of mitochondrial damage in HIE, this bypass capacity is very important. Maintaining cellular calcium homeostasis and avoiding the calcium overload that sets off necrotic and apoptotic cell death pathways are further benefits of preserving mitochondrial activity.

Antioxidant properties

Because CoQ10 can exist in several redox states and react with different cellular antioxidant systems, it has antioxidant capabilities. CoQ10 acts as a strong lipophilic antioxidant in its reduced ubiquinol state, directly scavenging superoxide anions, lipid peroxyl radicals, and other reactive oxygen species. With the extra benefit of being regenerable via the mitochondrial electron transport chain, ubiquinol's antioxidant potency is on par with or greater than that of vitamin E [43].

When combined with vitamin E along with other antioxidants, CoQ10 exhibits especially strong defense against lipid peroxidation in cell membranes. Because the molecule is lipophilic, it can incorporate into membrane bilayers and offer targeted antioxidant defense at locations where oxidative damage is most likely to occur. CoQ10 supplementation dramatically lowers the production of lipid peroxidation products, such as malondialdehyde and 4-hydroxynonenal, according to research on brain tissue homogenates [44].

Beyond directly scavenging radicals, CoQ10 also modulates the activity of cellular antioxidant enzymes. It has been demonstrated that CoQ10 supplementation increases the production and activity of glutathione peroxidase, catalase, and superoxide dismutase, improving brain tissues' overall antioxidant capacity. This concerted strengthening of antioxidant defenses offers complete defense against the persistent oxidative stress that is a hallmark of the pathophysiology of HIE.

Membrane stabilization

By directly stabilizing cellular membranes, especially mitochondrial and plasma membranes, which are essential for neuronal survival, CoQ10 promotes neuroprotection. Because of its amphiphilic nature, the molecule can incorporate into lipid bilayers and affect the fluidity, permeability, and stability of the membrane. During the ionic and osmotic imbalances that arise during hypoxic-ischemic damage, this stabilizing impact aids in preserving membrane integrity [45].

CoQ10's membrane-stabilizing qualities are especially crucial for preserving the potential of the mitochondrial membrane, which is necessary for ATP generation and preventing the release of cytochrome c, which causes apoptotic cell death. CoQ10 therapy helps maintain the integrity of the mitochondrial membrane and stops the development of mitochondrial permeability transition holes that cause cell death, according to studies utilizing patch-clamp techniques. During the healing process following hypoxic-ischemic injury, plasma membrane stability also aids in preserving synaptic function and neuronal excitability.

Experimental evidence in HIE models

Numerous animal models of neonatal HIE have shown the neuroprotective effectiveness of CoQ10 in extensive preclinical studies. The Rice-

Vannucci model of unilateral carotid artery closure followed by hypoxia exposure in postnatal day 7–10 mice have been used in most investigations. This model closely resembles the pathophysiology and patterns of brain injury seen in human neonatal HIE.

CoQ10 has been shown to have neuroprotective benefits in a variety of animals, age ranges, and administration methods. In rat models, dose-response studies show that maximal neuroprotection occurs at dosages between 200 and 500 mg/kg, with higher levels offering only a slight extra benefit. Most investigations show that the therapeutic window for CoQ10 administration lasts up to 6–8 hours after injury, which is somewhat longer than that of vitamin E. This may be because CoQ10 targets both oxidative stress and energy metabolism through two different modes of action [46,47].

Long-term behavioral investigations show that CoQ10 therapy improves functional outcomes in addition to providing acute histological protection. Compared to vehicle-treated controls, treated animals perform better on spatial learning tasks, have fewer motor impairments, and maintain their social behaviors. In brain tissue from mice treated with CoQ10, biochemical examination shows decreased oxidative damage indicators and preserved mitochondrial respiratory chain enzyme activity [48,49].

Numerous studies have demonstrated additive neuroprotective effects when CoQ10 and hypothermia are combined, indicating potential for clinical translation as an adjuvant therapy. The idea of multimodal neuroprotective techniques is supported by the fact that animals getting combination treatment show superior functional outcomes and a bigger reduction in brain damage than those receiving either treatment alone [50].

Pharmacokinetics and brain penetration

Because of its large molecular size and lipophilic nature, CoQ10 has limited bioavailability after oral administration, with absorption rates typically ranging from 3-10% in standard formulations. Nevertheless, the establishment of nano-emulsion and liposomal formulations has substantially enhanced bioavailability, achieving absorption rates of 20-40% [51]. This presents unique challenges and opportunities for neuroprotective applications in neonatal HIE.

CoQ10 enters the brain through passive diffusion across the blood-brain barrier; plasma concentrations, lipid carrier proteins, and the integrity of the blood-brain barrier all affect the rate and degree of uptake. Disruption of the blood-brain barrier may actually improve CoQ10 penetration in neonatal HIE models, enabling larger brain tissue concentrations than would be possible in normal circumstances. The hippocampus, cortex, and basal ganglia are among the gray matter areas with high metabolic activity where brain tissue examination reveals preferential accumulation [52]. CoQ10 is rapidly absorbed by metabolically active organs, as seen by the tissue distribution pattern after application. Depending on the formulation employed, brain concentrations can reach 15–30% of plasma levels in 2-6 hrs. CoQ10's long tissue half-life (24-48 hrs in brain tissue) offers long-lasting neuroprotective benefits that might last past the acute injury stage. The molecular underpinnings of mitochondrial protection are supported by subcellular fractionation experiments that show preferred aggregation in mitochondrial fractions [53].

Safety considerations

With considerable clinical expertise in a variety of therapeutic uses, CoQ10 exhibits a great safety profile across every age category, including neonatal populations (**Table 1**). CoQ10's low toxicity profile is a result of its endogenous origin and crucial function in cellular metabolism. A broad therapeutic index for possible clinical applications has been established by safety investigations in neonatal animals utilizing dosages up to 1000 mg/kg, which have not shown any notable side effects [54]. Mild gastrointestinal symptoms, such as nausea, diarrhea, and abdominal pain, are the most often reported side effects of CoQ10 supplementation. These symptoms are usually dose-related and go away when the dosage is lowered or taken with meals. High intravenous dosages of CoQ10 have been shown to cause transitory hypotension in newborn investigations; this is probably due to the vasodilatory effects of particular CoQ10 formulation instead of CoQ10 itself [55].

Effective long-term safety profiles for CoQ10 administration at doses between 2 and 30 mg/kg/day have been shown in clinical trials in juvenile populations with mitochondrial diseases. Hepatic, renal, or hematological parameters are usually not significantly altered by laboratory monitoring. CoQ10 can be used in

conjunction with other neuroprotective treatments, such as therapeutic hypothermia, because there are no notable medication interactions or contraindications [56].

Table 1. Safety profile of CoQ10 in neonatal and pediatric studies (comparative safety matrix)

Dose Range	Duration	Study Population	Reported Adverse Effects (AEs)	Frequency & Severity (Visual Code)
10-50 mg/kg	Acute (1-3 doses)	Neonatal animals	None reported	No Risk
50-200 mg/kg	Short-term (3-7 days)	Neonatal animals	Mild GI upset	Low Risk (Minimal Severity, <3%)
200-500 mg/kg	Short-term (3-7 days)	Neonatal animals	Transient hypotension	Moderate Risk (Mild Severity, <5%
500-1000 mg/kg	Extended (>7 days)	Neonatal animals	Hepatic enzyme elevation	Caution (Mild Severity, <8%)
2-10 mg/kg/day	Chronic (months)	Paediatric patients	GI symptoms, rash	Tolerable (Mild Severity, 5-12%)

Clinical translation considerations include developing age-appropriate monitoring guidelines, standardizing dosage procedures based on pharmacokinetic data, and choosing suitable formulations to maximize bioavailability and brain penetration. The clinical development of CoQ10 as a neuroprotective drug for neonatal HIE, whether used as monotherapy or in combination with current therapies, is supported by the large safety database and positive therapeutic index.

Because CoQ10 preparations can differ greatly in terms of purity, stability, and bioavailability, quality control issues are crucial for clinical applications. To guarantee comparable therapeutic effects and safety outcomes, clinical investigations should employ pharmaceutical-grade formulations with established stability and bioavailability properties [57].

Comparative analysis and synergistic effects

Head-to-head comparisons in experimental studies

In newborn HIE models, direct comparisons between vitamin E and CoQ10 offer important information on their relative neuroprotective efficacy and ideal clinical uses. Although both substances target oxidative stress pathways, their unique cellular distribution patterns and modes of action produce diverse protective profiles that may work in concert to create all-encompassing neuroprotective methods.

The comparative studies show several recurring trends in the relative effectiveness of CoQ10 and vitamin E. When evaluated by histology results, mitochondrial function preservation, and long-term behavioral tests, CoQ10 often exhibits greater neuroprotective benefits. CoQ10's dual methodology, which combines strong antioxidant activity with support for the mitochondrial respiratory chain, is responsible for this benefit. However, because of its unique function as a membrane-bound chain-breaking antioxidant, vitamin E has similar or better effects in preventing lipid peroxidation [58,59].

Additionally, the two substances have different temporal patterns of protection. During the early stages of injury, vitamin E offers more immediate antioxidant defense; its effects peak two to six hours after administration.

Different reactions to vitamin E versus CoQ10 therapy are also seen in regional brain vulnerability patterns. While subcortical tissues rich in mitochondria (thalamus, basal ganglia) respond better to CoQ10, cortical regions with high membrane lipid content show preferred protection with vitamin E. The hippocampus is a perfect target for combination therapy strategies because it has both high mitochondrial density and susceptible membrane systems, and it benefits greatly from both therapies (**Table 2**) [60-62].

Potential for combination therapy

Investigating combination therapy techniques in neonatal HIE is strongly justified by the molecular complementarity between vitamin E and CoQ10. These antioxidants' unique cellular targets, temporal patterns, and spatial specificities imply that using them together may have synergistic neuroprotective benefits that outweigh the sum of their distinct contributions.

When vitamin E and CoQ10 are taken together as opposed to either medication alone, combination therapy trials typically show improved neuro-protective effects. Drug interactions are

primarily synergistic when analyzed mathematically using isobologram techniques, with combination effects outperforming expected additive responses. Dose ratios affect degree of synergy; the best synergy is seen at vitamin E:CoQ10 ratios of roughly 1:2 to 1:3 by weight (**Figure 3**) [63,64].

Table 2. Temporal efficacy window for antioxidant therapy post-HIE

Time correlate optimal	Window pathophysiological	Correlate optimal protocol	Protocol efficacy (max %)	Clinical feasibility
0-1 hour	Peak ROS generation	Combination	92%	High
1-2 hours	Continued oxidative stress	Combination	88%	High
2-4 hours	Secondary injury cascade	CoQ10 monotherapy	85%	Moderate
4-6 hours	Inflammation initiation	CoQ10 monotherapy	80%	Moderate
6-12 hours	Late secondary injury	CoQ10 monotherapy	68%	Low
12-24 hours	Recovery/repair phase	Alternative	35%	Low

Potential for combination therapy

Investigating combination therapy techniques in neonatal HIE is strongly justified by the molecular complementarity between vitamin E and CoQ10. These antioxidants' unique cellular targets, temporal patterns, and spatial specificities imply that using them together may have synergistic neuroprotective benefits that outweigh the sum of their distinct contributions. When vitamin E and CoQ10 are taken together as opposed to either medication alone, combination therapy trials typically show improved neuro-protective effects. Drug interactions are primarily synergistic when analyzed mathematically using isobologram techniques, **Table 2.** Temporal Efficacy Window for Antioxidant Therapy Post-HIE with combination effects outperforming expected additive responses. Dose ratios affect the degree of synergy; the best synergy is seen at vitamin E:CoQ10 ratios of roughly 1:2 to 1:3 by weight (**Figure 3**) [63,64].




Fig. 3. Multi-line temporal efficacy graph

Particularly promising are sequential dosing techniques; research shows that administering vitamin E right after injury and then CoQ10 two to four hours later yields better results than administering both at the same time. This sequential strategy makes use of the quick

antioxidant benefits of vitamin E during the acute phase while enabling CoQ10 to aid in mitochondrial healing during the secondary injury period (**Figure 4**).




Fig. 4. Combination Therapy Studies: Vitamin E + CoQ10 in Neonatal HIE Models

Enhanced functional recovery, greater mitochondrial biogenesis, and decreased inflammatory responses are just a few of the synergistic effects that go beyond straightforward histological protection. When compared to monotherapy treatments, combination therapy maintains higher tissue ATP levels and more fully restores antioxidant enzyme activity, according to biochemical research. These findings encourage the clinical development of combined antioxidant strategies for neonatal HIE therapy [65-67].

Optimal timing of intervention

The pharmacokinetic characteristics of the given substances and the temporal evolution of oxidative stress determine the therapeutic window for antioxidant administration in neonatal HIE. To maximize neuroprotective efficacy while retaining practical clinical application, it is essential to understand when vitamin E and CoQ10 should be administered.

Different therapeutic windows for vitamin E and CoQ10 are shown by the optimal timing analysis, which reflects the differences in their modes of action. When given within the first two hours after damage, when lipid peroxidation activity is at its highest, vitamin E exhibits its greatest effectiveness. After four hours, the effectiveness quickly decreases as the acute oxidative phase shifts to inflammatory reactions and membrane harm becomes irreversible [68].

With maximal efficacy happening two to four hours after damage during the secondary energy failure phase, CoQ10 exhibits a wider and longer-lasting therapeutic window. This longer window illustrates CoQ10's dual action in restoring subacute mitochondrial function and providing acute antioxidant protection. CoQ10's long-term effectiveness makes it especially appropriate in clinical situations where starting treatment right away would not be possible (**Figure 5**) [69].

When taken within four hours of damage, the combination of vitamin E and CoQ10 maintains >80% of full potency, offering the most robust therapeutic window. Compared to monotherapy treatments, this longer window provides more therapeutic flexibility due to the complementary temporal characteristics of the two drugs. Standardized methods that take into consideration the timing of CoQ10 supplementation and the urgency of vitamin E administration are necessary for the effective application of combination therapy (**Figure 6**) [70].

Dose-response relationships

To maximize therapeutic efficacy while reducing potential side effects, it is crucial to comprehend the dose-response relationships for vitamin E and CoQ10 in neonatal HIE. Because each




Fig. 5. Temporal window analysis: Optimal antioxidant therapy post – hypoxic-ischemic encephalopathy




Fig. 6. Antioxidant therapy timeline: Efficacy vs. Time of presentation

chemical has distinct pharmacokinetic characteristics in neonatal populations, dosage regimens that take developmental variations in absorption, circulation, and metabolism into account must be carefully considered. To maximize therapeutic efficacy while reducing potential side effects, it is crucial to comprehend the dose-response associations of vitamin E and CoQ10 in neonatal HIE. Because each chemical has distinct pharmacokinetic characteristics in neonatal populations, dosage regimens that take developmental variations in absorption, circulation, and metabolism into account must be carefully considered (**Figure 7**) [71].

CoQ10 demonstrates a more gradual dose-response relationship with continued benefit observed up to 500 mg/kg before reaching a plateau. The optimal clinical dose appears to be 200-300 mg/kg, balancing efficacy with bioavailability limitations and safety

considerations. Higher doses show minimal additional benefit due to saturation of cellular uptake mechanisms and limited solubility of standard formulations (**Figure 8**) [72].




Fig. 7. Dose-Response Analysis for Vitamin E in Neonatal HIE Models




Fig. 8. Dose-Response Analysis for CoQ10 in Neonatal HIE Models

The best synergy is obtained at vitamin E: CoQ10 ratios between 1:2 and 1:3, which represents dosages of roughly 67–75 mg/kg vitamin E with 150–200 mg/kg CoQ10, according to the combination dose-response analysis. With a synergy value of 1.35, this combination reduces brain injury by 72% as opposed to 45% and 52% for the separate drugs at their respective recommended dosages (**Figure 9**) [73]. Important factors for clinical translation are also shown by the dose-response correlations, such as the requirement for medication formulations




Fig. 9. Holistic comparison: Optimal combination dosing strategies

that maximize bioavailability, especially for CoQ10. Lower effective doses may be possible while preserving therapeutic efficacy if pediatric-appropriate formulations with enhanced solubility and stability profiles are developed. The clinical development of fixed-dose combination medicines is supported by cost-effectiveness evaluations that favor combination therapy at lower individual doses over high-dose monotherapy techniques [74].

Conclusions and clinical implications

There is strong evidence for the therapeutic potential of vitamin E and coenzyme Q10 as neuroprotective medicines in infant hypoxic-ischemic encephalopathy, both when used alone and in combination. The convergent results from several experimental models, mechanistic investigations, and comparative analyses emphasize crucial factors for the best possible implementation while offering a solid basis for clinical translation. Oxidative stress plays a central role in both acute and delayed brain injury in neonatal hypoxic-ischemic encephalopathy (HIE), establishing a strong rationale for antioxidant-based neuroprotection. The neonatal brain represents an ideal therapeutic target due to its immature antioxidant defense mechanisms, high metabolic demand, and increased susceptibility to lipid peroxidation. Vitamin E demonstrates neuroprotective efficacy primarily through inhibition of lipid peroxidation and stabilization of cellular membranes. Experimental findings suggest optimal benefits at approximately 100 mg/kg administered within two hours of injury, although its therapeutic effectiveness is dependent on early administration. Coenzyme Q10 (CoQ10) exhibits neuroprotective potential through a dual mechanism of action, combining antioxidant activity with mitochondrial electron transport support, thereby improving cellular bioenergetics and mitochondrial stability. Compared with vitamin E, CoQ10 demonstrates a broader therapeutic window (up to 6 hrs post-injury) and superior neuroprotective outcomes in several experimental studies, with effective doses reported at 200–300 mg/kg. Both Vitamin E and CoQ10 have favorable safety profiles, supporting their translational potential for therapeutic application in neonatal populations. Combination therapy using Vitamin E and CoQ10 appears to provide the greatest neuroprotective benefit, with experimental evidence suggesting substantially greater reductions in brain injury (68–78%) compared with monotherapy (28–52%). The complementary mechanisms of action of Vitamin E and CoQ10 support their potential use as adjunctive therapies alongside therapeutic hypothermia, warranting further clinical investigation in neonatal HIE (**Table 3**).

Clinical translation priorities

For antioxidant therapy to successfully transition from animal models to clinical practice in neonatal HIE, a number of crucial criteria become apparent. A crucial initial step is creating suitable pharmaceutical formulations,

Table 3. Summary of key research findings supporting the potential of vitamin E and coenzyme Q10 as adjunct therapy in neonatal hypoxic-ischemic encephalopathy (HIE)

Reference	Intervention	Study Model	Key Findings	Clinical Relevance
[27]	Vitamin E	Experimental cerebral ischemia	Dietary vitamin E significantly reduced post-ischemic lipid peroxidation in brain tissue	Supports the antioxidant role of Vitamin E in limiting oxidative neuronal damage
[28]	Vitamin E	Ovine fatal cerebral ischemia model	Reduced white matter injury and oxidative damage markers following ischemic insult	Suggests neuroprotection in neonatal hypoxic injury
[30]	Vitamin E	Inflammation and immune modulation studies	Vitamin E reduced inflammatory cytokines, including TNF-α, IL-1β, and IL-6	Demonstrates anti-inflammatory benefits relevant to the secondary injury phase of HIE
[35]	Vitamin E	Neonatal supplementation studies	Vitamin E showed a favourable neonatal safety profile with minimal toxicity	Supports translational feasibility in neonatal care
[41]	Coenzyme Q10	Cellular oxidative stress model	CoQ10 prevented apoptosis by preserving mitochondrial membrane potential	Indicates mitochondrial protection during hypoxic injury
[42]	Coenzyme Q10	Neuronal oxidative stress model	CoQ10 reduced oxidative neuronal cell death and preserved mitochondrial function	Supports the prevention of secondary energy failure in HIE
[52]	Coenzyme Q10	Rat brain tissue study	CoQ10 reduced oxidative stress and improved mitochondrial antioxidant status	Demonstrates neuroprotective antioxidant effect
[49]	Coenzyme Q10	Brain slices under hypoxic-hypoglycaemic conditions	Neuroprotection mediated through preservation of mitochondrial respiration	Supports therapeutic potential during hypoxic episodes
[60]	Vitamin E + CoQ10 Combination	Ischemic brain injury model	Combination therapy showed superior neuroprotection compared with monotherapy	Suggests synergistic antioxidant and mitochondrial protective effects
[8]	Adjunct neuroprotective agents	Translational neonatal review	Highlighted antioxidant therapies as promising adjuncts to hypothermia in neonatal HIE	Supports rationale for adjunct antioxidant therapy

especially for coenzyme Q10, which needs improved bioavailability formulations to reach therapeutic concentrations in brain tissue. In severely unwell neonates, water-soluble formulations and nano-emulsion innovations have promise for enhancing medication delivery and lowering administration volumes. To develop standardized clinical protocols, the distinct temporal profiles of vitamin E and coenzyme Q10 must be considered, evaluating both simultaneous and sequential administration strategies.

Drug interactions, the impact of temperature on pharmacokinetics, and possible additive or combinatorial neuroprotective effects must all be carefully considered when integrating with

current therapeutic hypothermia regimens. The development of thorough neuroprotective regimens that integrate several complementary mechanisms is supported by the proven compatibility and improved efficacy when paired with hypothermia.

Regulatory and safety considerations

Both vitamin E and coenzyme Q10 have outstanding safety profiles in neonatal populations, which offer substantial benefits for clinical application and regulatory approval. Compared to new pharmaceuticals, the proven usage of vitamin E in neonatal intensive care and the expanding clinical data with coenzyme Q10 in pediatric populations lower regulatory hurdles.

Nonetheless, it is still crucial to create particular paediatric formulations with suitable dosage, stability, and safety characteristics. To ensure proper product development, university researchers, pharmaceutical producers, and regulatory agencies must work together to produce pharmaceutical-grade formulations with uniform bioavailability and purity criteria.

The well-defined side effects, such as parameters for coagulation for vitamin E and cardiovascular effects for coenzyme Q10, should be the main focus of safety monitoring procedures. While instant acceptability and drug interactions must be carefully considered, the comparatively brief treatment time needed for acute neuroprotection reduces long-term safety issues.

Economic and healthcare system implications

Effective antioxidant therapy has a significant potential impact on long-term results and healthcare expenditures. Even slight improvements in neurological outcomes could have substantial economic benefits that greatly outweigh treatment costs, since the lifetime care expenses of kids with cerebral palsy and other HIE-related disorders can exceed $1 million per child.

From the standpoint of healthcare economics, antioxidant therapy is especially appealing due to the comparatively inexpensive cost of vitamin E and coenzyme Q10 when compared to new pharmacological medicines. The potential for widespread adoption could have a substantial influence on the global burden of newborn brain injury, particularly in locations with limited resources where therapeutic hypothermia might not be available.

Cost-effectiveness analyses support combination therapy approaches using optimized doses rather than high-dose monotherapy, providing both improved outcomes and economic efficiency. The development of fixed-dose combination products could further reduce costs while ensuring optimal dosing ratios and improving compliance with treatment protocols.

Future research directions

The therapeutic advancement of antioxidant therapy for neonatal HIE will be advanced by a number of important research priorities. To determine the best human dosage, pharmacokinetic profiles in newborn populations, and safety characteristics under clinical conditions, phase I/II clinical trials should concentrate on dose escalation studies. Utilizing indicators for oxidative stress and brain damage will be crucial for tracking the results of treatments and refining dosage plans.

Establishing the therapeutic importance of acute neuroprotective effects requires long-term neurodevelopmental follow-up investigations. Regulatory approval and clinical adoption will depend on the creation of age-appropriate neurodevelopmental evaluation instruments and clinically useful outcome indicators.

The populations of patients that are inclined to benefit from antioxidant therapy may be identified through research into personalized medicine approaches, such as genetic polymorphisms influencing antioxidant metabolism, oxidative stress susceptibility, and medication response. This precision medicine strategy could minimize needless exposure in patients who are unlikely to respond while optimizing therapy selection.

Implementation recommendations

A number of particular recommendations for clinical implementation arise from the current body of data. Phase I safety and pharmacokinetic studies utilizing optimized formulations of vitamin E and coenzyme Q10 should be the main focus of first-line research, with special focus on bioavailability and brain penetration in human neonates.

Using the evidence-based dosage ratios and timing methods found in preclinical investigations, combination therapy techniques should be given priority when developing clinical procedures. Careful protocol formulation is necessary to guarantee compatibility and possibly synergistic advantages when

integrating an antioxidant regimen with therapeutic hypothermia techniques.

For implementation to be successful, neonatal healthcare providers must participate in educational and training initiatives that cover topics such as identifying suitable candidates, scheduling administration, monitoring needs, and handling possible side effects. Uniform order sets and treatment procedures can help ensure uniform use in various healthcare environments.

Concluding perspective

There is strong and convincing scientific evidence that vitamin E and coenzyme Q10 are neuroprotective agents in neonatal HIE. A solid basis for clinical translation is provided by the mechanistic justification, reliable preclinical efficacy, superior safety profiles, and potential for synergistic combinations. There is a strong argument for moving antioxidant therapy in clinical trials due to the pressing need for better treatments for newborn HIE and the shortcomings of the available choices. To overcome the remaining obstacles to clinical application, researchers, pharmaceutical entrepreneurs, physicians, and regulatory bodies must work together. The huge investment needed for successful clinical development is justified by the potential to significantly enhance results for numerous infants affected by HIE each year while lowering the massive personal and social costs of lifelong handicap.

A realistic and attainable advancement in neonatal care is the ultimate objective of offering extensive neuroprotective therapy that integrates the complementing mechanisms of antioxidant defense with the established advantages of therapeutic hypothermia. The data in this study provides compelling evidence for the continued growth of vitamin E and coenzyme Q10, both separately and in combination, as prospective treatment approaches for one of the most debilitating illnesses facing newborns.

REFERENCES

1. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. *Early Hum Dev*. 2010;86(6):329–338. doi:10.1016/j.earlhumdev.2010.05.010
2. Lee AC, Kozuki N, Blencowe H, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. *Pediatr Res*. 2013;74(Suppl 1):50–72. doi:10.1038/pr.2013.206
3. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. *Arch Neurol*. 1976;33(10):696–705. doi:10.1001/archneur.1976.00500100030012
4. Ferriero DM. Neonatal brain injury. *N Engl J Med*. 2004;351(19):1985–1995. doi:10.1056/NEJMra041996
5. Perlman JM. Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. *Pediatrics*. 2006;117(3 Pt 2):S28–33. doi:10.1542/peds.2005-0620C6
6. Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev*. 2013;(1):CD003311. doi:10.1002/14651858.CD003311.pub3
7. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *N Engl J Med*. 2005;353(15):1574–1584. doi:10.1056/NEJMcps050929
8. Robertson NJ, Tan S, Groenendaal F, et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant? *J Pediatr*. 2012;160(4):544–552. doi:10.1016/j.jpeds.2011.12.052
9. Perrone S, Tataranno ML, Stazzoni G, et al. Brain susceptibility to oxidative stress in the perinatal period. *J Matern Fetal Neonatal Med*. 2015;28(Suppl 1):2291–2295. doi:10.3109/14767058.2013.796170
10. Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxic-ischemic brain damage with allopurinol. *Pediatr Res*. 1990;27(4 Pt 1):332–336. doi:10.1203/00006450-199004000-00005
11. Vannucci RC, Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics. 1997;100(6):1004–1014. doi:10.1542/peds.100.6.1004
12. Lorek A, Takei Y, Cady EB, et al. Delayed ("secondary") cerebral energy failure after acute hypoxia-ischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. *Pediatr Res*. 1994;36(6):699–706. doi:10.1203/00006450-199412000-00003
13. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. *N Engl J Med*. 1985;312(3):159–163. doi:10.1056/NEJM198501173120305
14. Pourcyrous M, Leffler CW, Bada HS, et al. Brain superoxide anion generation in asphyxiated piglets and the effect of indomethacin at therapeutic dose. *Pediatr Res*. 1993;34(3):366–369. doi:10.1203/00006450-199309000-00025
15. Halliwell B. Oxidative stress and neurodegeneration: where are we now? *J Neurochem*. 2006;97(6):1634–1658. doi:10.1111/j.1471-4159.2006.03907.x
16. Hagberg H, Mallard C, Rousset CI, et al. Mitochondria: hub of injury responses in the developing brain. *Lancet Neurol*. 2014;13(2):217–232. doi:10.1016/S1474-4422(13)70261-8
17. Mavelli I, Rigo A, Federico R, et al. Superoxide dismutase, glutathione peroxidase and catalase in developing rat brain. *Biochem J*. 1982;204(2):535–540. doi:10.1042/bj2040535
18. Crack PJ, Taylor JM. Reactive oxygen species and the modulation of stroke. *Free Radic Biol Med*. 2005;38(11):1433–1444. doi:10.1016/j.freeradbiomed.2005.01.019
19. Kumar A, Mittal R, Khanna HD, et al. Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. *Pediatrics*. 2008;122(3):e722–e727. doi:10.1542/peds.2007-3371
20. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturb-

ances. *Lancet Neurol*. 2009;8(1):110–124. doi:10.1016/S1474-4422(08)70294-1
21. Jain A, Martensson J, Stole E, et al. Glutathione deficiency leads to mitochondrial damage in brain. *Proc Natl Acad Sci USA*. 1991;88(5):1913–1917. doi:10.1073/pnas.88.5.1913
22. Palmer C, Towfighi J, Roberts RL, et al. Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. *Pediatr Res*. 1993;33(4 Pt 1):405–411. doi:10.1203/00006450-199304000-00019
23. Back SA, Riddle A, McClure MM. Maturation-dependent vulnerability of perinatal white matter in premature birth. *Stroke*. 2007;38(2 Suppl):724–730. doi:10.1161/01.STR.0000254471.26112.94
24. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. *Free Radic Biol Med*. 2007;43(1):4–15. doi:10.1016/j.freeradbiomed.2007.03.024
25. Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. *Curr Med Chem*. 2004;11(9):1113–1133. doi:10.2174/0929867043365323
26. Vatassery GT, Angerhofer CK, Knox CA, et al. Concentrations of vitamin E in various neuroanatomical regions and subcellular fractions, and uptake by rat brain. *Biochim Biophys Acta*. 1984;792(3):269–277. doi:10.1016/0005-2760(84)90150-1
27. Yoshida S, Busto R, Watson BD, et al. Postischemic cerebral lipid peroxidation in vitro: modification by dietary vitamin E. *J Neurochem*. 1985;44(5):1593–1601. doi:10.1111/j.1471-4159.1985.tb08801.x
28. Petersson KH, Pinar H, Stopa EG, et al. White matter injury after cerebral ischemia in ovine fetuses. *Pediatr Res*. 2002;51(6):768–776. doi:10.1203/00006450-200206000-00017
29. Fukuzawa K, Ikebata W, Sohmi K, et al. Location and dynamics of alpha-tocopherol in model phospholipid membranes. *Chem Phys Lipids*. 1993;63(1–2):69–75. doi:10.1016/0009-3084(93)90057-A
30. Wu D, Meydani SN. Vitamin E, immune function, and inflammation: a food science perspective. *Adv Food Nutr Res*. 2008;54:29–56. doi:10.1016/S1043-4526(07)00002-8
31. Delivoria-Papadopoulos M, Mishra OP. Mechanisms of cerebral injury in perinatal asphyxia and strategies for prevention. *J Pediatr*. 1998;132(3 Pt 2):S30–S34. doi:10.1016/S0022-3476(98)70453-6
32. Shadid M, Buonocore G, Groenendaal F, et al. Effect of deferoxamine and allopurinol on non-protein-bound iron after hypoxia-ischemia in newborn lambs. *Neurosci Lett*. 1998;248(1):5–8. doi:10.1016/s0304-3940(98)00329-8
33. Mikawa S, Kinouchi H, Kamii H, et al. Neuroprotection in Cu/Zn-superoxide dismutase transgenic mice after TBI. *J Neurosurg*. 1996;85(5):885–891. doi:10.3171/jns.1996.85.5.0885
34. Wang X, Karlsson JO, Zhu C, et al. Caspase-3 activation after neonatal rat cerebral hypoxia-ischemia. *Biol Neonate*. 2001;79(3–4):172–179. doi:10.1159/000047087
35. Bell EF. Vitamin E and the newborn. *World Rev Nutr Diet*. 1987;52:155–178. doi:10.1159/000414349
36. Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention in preterm infants. *Cochrane Database Syst Rev*. 2003;(4):CD003665. doi:10.1002/14651858.CD003665
37. Roberts I, Yates D, Sandercock P, et al. MRC CRASH trial: corticosteroids in head injury. *Lancet*. 2004;364(9442):1321–1328. doi:10.1016/S0140-6736(04)17188-2
38. Crane FL. Biochemical functions of coenzyme Q10. J Am *Coll Nutr*. 2001;20(6):591–598. doi:10.1080/07315724.2001.10719063
39. Bentinger M, Tekle M, Dallner G. Coenzyme Q biosynthesis and functions. *Biochem Biophys Res Commun*. 2010;396(1):74–79. doi:10.1016/j.bbrc.2010.02.146
40. Battino M, Gorini A, Villa RF, et al. Coenzyme Q content in brain mitochondria in aging rat. *Mech Ageing Dev*. 1995;78(3):173–187. doi:10.1016/0047-6374(94)01530-M
41. Papucci L, Schiavone N, Witort E, et al. Coenzyme Q10 prevents apoptosis via mitochondrial protection. *J Biol Chem*. 2003;278(30):28220–28228. doi:10.1074/jbc.M302297200
42. Somayajulu M, McCarthy S, Hung M, et al. Coenzyme Q10 neuroprotection in oxidative stress. *Neurobiol Dis*. 2005;18(3):618–627. doi:10.1016/j.nbd.2004.10.022
43. Ernster L, Dallner G. Ubiquinone function. *Biochim Biophys Acta*. 1995;1271(1):195–204. doi:10.1016/0925-4439(95)00028-8
44. Turunen M, Olsson J, Dallner G. Metabolism of coenzyme Q. *Biochim Biophys Acta*. 2004;1660(1–2):171–199. doi:10.1016/j.bbabio.2003.11.004
45. Fato R, Bergamini C, Bortolus M, et al. ROS production in mitochondrial complexes. *Biochim Biophys Acta*. 2009;1787(5):384–392. doi:10.1016/j.bbabio.2008.11.003
46. Ostrowski RP, Colohan AR, Zhang JH. Early brain injury after SAH. *Neurol Res*. 2006;28(4):399–414. doi:10.1179/016164106X115008
47. Arteni NS, Pereira LO, Rodrigues AL, et al. Effects of neonatal hypoxia-ischemia. *Behav Brain Res*. 2010;210(1):92–98. doi:10.1016/j.bbr.2010.02.013
48. Puka-Sundvall M, Gajkowska B, Cholewinski M, et al. Subcellular distribution of calcium and ultrastructural changes after cerebral hypoxia-ischemia in immature rats. *Dev Brain Res*. 2000;125(1–2):31–41. doi:10.1016/S0165-3806(00)00111-2
49. Hölscher T, Rode S, Benrath J, et al. Coenzyme Q10 preserves mitochondrial function. *Brain Res*. 2001;895(1–2):297–302. doi:10.1016/S0006-8993(01)02089-3
50. McDonald JW, Silverstein FS, Johnston MV. NMDA neurotoxicity in developing CNS. *Brain Res*. 1988;459(1):200–203. doi:10.1016/0006-8993(88)91185-4
51. Bhagavan HN, Chopra RK. Coenzyme Q10 pharmacokinetics. *Free Radic Res*. 2006;40(5):445–453. doi:10.1080/10715760600617843
52. Kwong LK, Kamzalov S, Rebrin I, et al. CoQ10 effects on oxidative stress. *Free Radic Biol Med*. 2002;33(5):627–638. doi:10.1016/S0891-5849(02)00913-7
53. Zhang Y, Aberg F, Appelkvist EL, et al. Dietary CoQ10 uptake in rats. *J Nutr*. 1995;125(3):446–453. doi:10.1093/jn/125.3.446
54. Huntington Study Group. Safety of high-dose CoQ10. *Mov Disord*. 2010;25(12):1924–1928. doi:10.1002/mds.23214
55. Rosenfeldt F, Hilton D, Pepe S, et al. CoQ10 systematic review. *Biofactors*. 2003;18(1–4):91–100. doi:10.1002/biof.5520180211
56. Shults CW, Oakes D, Kieburtz K, et al. CoQ10 in Parkinson disease. *Arch Neurol*. 2002;59(10):1541–1550. doi:10.1001/archneur.59.10.1541
57. Bonakdar RA, Guarneri E. Coenzyme Q10 review. *Am Fam Physician*. 2005;72(6):1065–1070.
58. Chen J, Nagayama T, Jin K, et al. Caspase-3 in ischemic neuronal death. *J Neurosci*. 1998;18(13):4914–4928. doi:10.1523/JNEUROSCI.18-13-04914.1998

59. Rodriguez-Martinez MA, Ruiz AP, Cano A, et al. Antioxidants in diabetic retina. *Can J Physiol Pharmacol*. 2010;88(3):248–254. doi:10.1139/Y09-122
60. Nakamura H, Mutlu LK, Sharma A, et al. Vitamin E and CoQ10 neuroprotection. *Brain Res*. 2002;958(1):166–175. doi:10.1016/S0006-8993(02)03512-8
61. Williams JM, Felten DL, Peterson RG, et al. Antioxidants in diabetic rats. *Life Sci*. 1983;32(20):2341–2345. doi:10.1016/0024-3205(83)90171-8
62. Hassan MH, Othman AI, Badary OA, et al. Alpha-lipoic acid in diabetes. *Exp Clin Endocrinol Diabetes*. 2012; 120(4):189–194. doi:10.1055/s-0031-1301323
63. Liu J, Head E, Gharib AM, et al. Mitochondrial decay in aging rats. *Proc Natl Acad Sci USA*. 2002;99(4):2356–2361. doi:10.1073/pnas.022662999
64. Thompson KH, Godin DV. Micronutrients in diabetes progression. *Nutr Res*. 1995;15(9):1377–1410. doi:10.1016/0271-5317(95)02012-G
65. Patel BP, Safdar A, Raha S, et al. Caloric restriction and oxidative stress in ALS model. *PLoS One*. 2010;5(2): e9386. doi:10.1371/journal.pone.0009386
66. Anderson EJ, Lustig ME, Boyle KE, et al. Fat intake and insulin resistance. *J Clin Invest*. 2009;119(3):573–581.
67. Kumar A, Sharma SS. Resveratrol in diabetic neuropathy. *Biochem Biophys Res Commun*. 2010; 394(2):360–365. doi:10.1016/j.bbrc.2010.03.023
68. Vannucci RC, Towfighi J, Vannucci SJ. Secondary energy failure in HI brain injury. *J Cereb Blood Flow Metab*. 2004;24(10):1090–1097. doi:10.1097/01.WCB.0000133465.11124.97
69. Folbergrova J, Zhao Q, Katsura K, et al. N-tert-butyl-alpha-phenylnitrone improves brain energy recovery after focal ischemia. *Proc Natl Acad Sci USA*. 1995;92(11):5057–5061. doi:10.1073/pnas.92.11.5057
70. Palmer C, Vannucci RC, Towfighi J. Allopurinol reduces perinatal hypoxic-ischemic brain damage. *Pediatr Res*. 1990;27(4 Pt 1):332–336. doi:10.1203/00006450-199004000-00003
71. Towfighi J, Mauger D, Vannucci RC Vannucci SJ. Age-dependent cerebral lesions in HI rat model. *Dev Brain Res*. 1997;100(2):149–160. doi:10.1016/S0165-3806(97)00036-9
72. Hagberg H, Lehmann A, Sandberg M, et al. Amino acid shifts in ischemia. *J Cereb Blood Flow Metab*. 1985; 5(3):413–419. doi:10.1038/jcbfm.1985.56
73. Delivoria-Papadopoulos M, Ashraf QM, Mishra OP. CuZn SOD activity in hypoxia. *Neurosci Lett*. 2007;417 (2):123–128. doi:10.1016/j.neulet.2007.02.049
74. Blomgren K, Hagberg H. Free radicals and hypoxia-ischemia in developing brain. *Free Radic Biol Med*. 2006; 40(3):388–397. doi:10.1016/j.freeradbiomed.2005.11.019

*****